Related Experiment Video
Updated: Dec 2, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumococcal disease in Thailand
Amgad Gamil1, Kulkanya Chokephaibulkit2, Wanatpreeya Phongsamart2
1Pfizer Inc., Medical and Scientific Affairs, Vaccines, Emerging Markets, PO Box 502749, Dubai, United Arab Emirates.
Pneumococcal disease is most common in young children and the elderly in Thailand. Pneumococcal conjugate vaccines (PCVs) show high efficacy against prevalent serotypes, yet are not in the national immunization program.
Area of Science:
- Public Health
- Epidemiology
- Vaccinology
Background:
- Pneumococcal disease remains a significant public health concern globally and in Thailand.
- Invasive pneumococcal disease (IPD) incidence and hospitalization rates are highest in children under 5 and the elderly in Thailand.
- Understanding serotype prevalence and antibiotic resistance is crucial for effective prevention strategies.
Purpose of the Study:
- To review the epidemiology of pneumococcal disease in Thailand.
- To analyze serotype prevalence and antibiotic resistance patterns.
- To evaluate the potential impact of pneumococcal conjugate vaccines (PCVs) on disease burden and discuss national vaccination recommendations.
Main Methods:
- Literature review of epidemiological data on pneumococcal disease in Thailand.
- Analysis of serotype distribution and antibiotic resistance profiles of Streptococcus pneumoniae isolates.
- Assessment of PCV10 and PCV13 coverage against prevalent serotypes in different age groups.
Main Results:
- The most prevalent serotype in Thailand is 6B, covered by both PCV10 and PCV13.
- PCV10 and PCV13 are estimated to cover 48.8%-74% and 73.2%-92% of isolates in children under 5, respectively.
- High rates of antibiotic resistance were observed for erythromycin, cefuroxime, and penicillin. PCVs are not currently part of the Thai national immunization program.
Conclusions:
- Pneumococcal conjugate vaccines (PCVs) have the potential to significantly reduce the burden of pneumococcal disease in Thailand across all age groups, especially in children and the elderly.
- Despite demonstrated efficacy and cost-effectiveness, PCVs are not included in the Thai national immunization program.
- Further implementation of PCVs in Thailand's national immunization program is recommended to reduce disease incidence and combat antibiotic resistance.
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

